Is There a Vascepa Generic Available?
No Vascepa (icosapent ethyl) generic is approved or available in the US as of October 2024. The brand remains the only option, with patents blocking generic entry until at least 2030.[1][2]
When Will Vascepa Generics Launch?
Amarin's key patents expire between 2027 and 2030, but FDA granted 7-year orphan drug exclusivity for hypertriglyceridemia until December 2029, delaying generics further. Multiple ANDA filers (Dr. Reddy's, Hikma, MSN) face ongoing patent litigation, with some tentative approvals but no final nods.[2][3]
What Would Vascepa Generics Cost?
No market pricing exists yet, but generics typically launch at 70-90% below brand prices. Vascepa's list price is ~$300-350 for 120 capsules (1g each, 30-day supply); generics could hit $30-100 monthly, depending on pharmacy and insurance. Real costs await FDA approval and competition.[1][4]
Why No Generics Despite Expired Patents?
Some early patents lapsed, but later ones (e.g., formulation, use in CV risk reduction) extend protection. Patent challenges continue in court; a loss for Amarin could accelerate entry by 2026-2027.[2]
Vascepa Brand Pricing and Savings Options
| Dose/Supply | List Price | With Coupon/Card |
|-------------|------------|------------------|
| 1g, 120 caps (30 days) | $298-$355 | $25-$50 [4][5] |
| 0.5g, 240 caps (30 days) | $298-$355 | $25-$50 |
GoodRx or manufacturer coupons often drop copays to $25/month for eligible patients. Medicare caps out-of-pocket at $2,000/year in 2025.[4][5]
How Does Vascepa Compare to Alternatives?
| Drug | Type | Monthly Cost (Generic/Brand) | Key Difference |
|------|------|------------------------------|---------------|
| Lovaza | Brand (mix of EPA/DHA) | $250-$300 (no generic) | Less pure EPA; similar triglycerides effect |
| Generic fish oil | OTC | $10-$20 | Weaker CV data; not FDA-approved for Vascepa indications |
| Fenofibrate (generic) | Prescription | $10-$30 | Statin combo for triglycerides; different CV profile[6] |
Vascepa targets high triglycerides + CV risk; alternatives lack its REDUCE-IT trial backing.[6]
Sources:
[1] FDA Orange Book
[2] DrugPatentWatch.com - Vascepa Patents
[3] Amarin SEC Filings
[4] GoodRx - Vascepa Pricing
[5] SingleCare Coupons
[6] FDA Labels